| Literature DB >> 24031657 |
Juan Manuel Talia1, Nora Beatriz Debattista, Nora Beatriz Pappano.
Abstract
Staphylococcus aureus, the most virulent Staphylococcus species, is also the prevalent pathogen isolated from hospitalized patients and the second most common from patients in outpatient settings. In general, bacteria have the genetic ability to transmit and acquire resistance to drugs, which are utilized as therapeutic agents. Related studies of antimicrobial activity indicate that crude extracts containing flavonoids, triterpenes and steroids have showed significative activity against several Staphylococcus aureus strains. Combination effects between flavonoids and antibiotics also have been reported. The aim of the present work was to investigate in vitro synergism between several chalcones substituted in combination with oxacillin, an antibiotic used conventionally against S. aureus ATCC 43 300 that is resistant to meticillin, using the kinetic turbidimetric method developed earlier. The results were satisfactory for all assayed combinations and in accordance with the mechanism of bacteriostatic inhibition previously proposed, except for 2´,4´-dihydroxy-3´-methoxychalcone - oxacillin. The best combination was 2´,3´-dihydroxychalcone -oxacillin (MIC: 11.2 µg/mL). Further investigations are needed to characterize the interaction mechanism with antibiotics. Thus, chalcones - oxacillin combination could lead to the development of new antibiotics against methicillin resistant S. aureus infection.Entities:
Keywords: S. aureus; antimicrobial; combinations; oxacillin; substituted chalcones
Year: 2011 PMID: 24031657 PMCID: PMC3769842 DOI: 10.1590/S1517-838220110002000010
Source DB: PubMed Journal: Braz J Microbiol ISSN: 1517-8382 Impact factor: 2.476
Figure 1Structure of compounds: 1: 2´,3- dihydroxychalcone; 2: 2´,4- dihydroxychalcone; 3: 2´,4´- dihydroxychalcone; 4: 2´,4´,3- trihydroxychalcone; 5: 2´,4´-dihydroxy-3´-methoxychalcone.
Specific growth rates and minimal inhibitory concentration for all systems assayed against a methicillin-resistant Staphylococcus aureus strain.
| Chalcone | Concentration 5.00 (μg.mL-1) | MIC μg.mL-1 | |||||
|---|---|---|---|---|---|---|---|
| 0 | 5.00 | 10.0 | 15.0 | 20.0 | |||
| 1 | µ (isolated) | 0.0465 | 0.0380 | 0.0158 | 0.00130 | 0 | 15.8 |
| µ (comb) | 0.0465 | 0.0231 | 0.00616 | 0 | 0 | 11.2 | |
| 2 | µ (isolated) | 0.0453 | 0.0389 | 0.0350 | 0.0314 | 0.0312 | 45.0 |
| µ (comb) | 0.0453 | 0.0150 | 0.0115 | 0.0112 | 0.00653 | 22.4 | |
| µ (isolated) | 0.0476 | 0.0373 | 0.0247 | 0.00425 | 0.000400 | 20.1 | |
| 3 | µ (comb) | 0.0476 | 0.0296 | 0.00928 | 0.00343 | 0 | 15.3 |
| 4 | µ (isolated) | 0.0459 | 0.0386 | 0.0314 | 0.0254 | 0.0131 | 30.8 |
| µ (comb) | 0.0459 | 0.0279 | 0.0197 | 0.0157 | 0.00719 | 22.5 | |
| 5 | µ (isolated) | 0.0464 | 0.0391 | 0.0348 | 0.0292 | 0.0244 | 42.5 |
| µ (comb) | 0.0464 | 0.00988 | 0.00866 | 0.00818 | 0.00766 | ∞ | |
Minimal inhibitory concentration and percentual bacteriostatic efficiency of isolated chalcones and of chalcones-oxacillin combinations against a methicillin-resistant Staphylococcus aureus strain.
| Chalcone | MIC (comb) | PBE (isolated) | PBE(comb) | |
|---|---|---|---|---|
| 1 | 11.2 | 6.33 | < | 8.93 |
| 2 | 22.4 | 2.22 | << | 4.46 |
| 3 | 15.3 | 4.97 | << | 6.53 |
| 4 | 22.5 | 3.25 | < | 4.44 |
| 5 | 73.9 | 2.35 | >>> | |